TY - JOUR
T1 - The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against cryptococcus neoformans and cryptococcus gattii
AU - Lockhart, Shawn R.
AU - Fothergill, Annette W.
AU - Iqbal, Naureen
AU - Bolden, Carol B.
AU - Grossman, Nina T.
AU - Garvey, Edward P.
AU - Brand, Stephen R.
AU - Hoekstra, William J.
AU - Schotzinger, Robert J.
AU - Ottinger, Elizabeth
AU - Patterson, Thomas F.
AU - Wiederhold, Nathan P.
N1 - Publisher Copyright:
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
PY - 2016/4
Y1 - 2016/4
N2 - The in vitro activities of the novel fungal Cyp51 inhibitor VT-1129 were evaluated against a large panel of Cryptococcus neoformans and Cryptococcus gattii isolates. VT-1129 demonstrated potent activities against both Cryptococcus species as demonstrated by low MIC50and MIC90values. For C. gattii, the in vitro potency was maintained against all genotypes. In addition, significantly lower geometric mean MICs were observed for VT-1129 than for fluconazole against C. neoformans, including isolates with reduced fluconazole susceptibility.
AB - The in vitro activities of the novel fungal Cyp51 inhibitor VT-1129 were evaluated against a large panel of Cryptococcus neoformans and Cryptococcus gattii isolates. VT-1129 demonstrated potent activities against both Cryptococcus species as demonstrated by low MIC50and MIC90values. For C. gattii, the in vitro potency was maintained against all genotypes. In addition, significantly lower geometric mean MICs were observed for VT-1129 than for fluconazole against C. neoformans, including isolates with reduced fluconazole susceptibility.
UR - http://www.scopus.com/inward/record.url?scp=84963717381&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963717381&partnerID=8YFLogxK
U2 - 10.1128/AAC.02770-15
DO - 10.1128/AAC.02770-15
M3 - Article
C2 - 26787697
AN - SCOPUS:84963717381
SN - 0066-4804
VL - 60
SP - 2528
EP - 2531
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 4
ER -